scPharmaceuticals Inc. (NASDAQ:SCPH) Short Interest Down 15.0% in March

scPharmaceuticals Inc. (NASDAQ:SCPH - Get Free Report) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 4,820,000 shares, a decline of 15.0% from the March 15th total of 5,670,000 shares. Based on an average daily volume of 441,300 shares, the short-interest ratio is presently 10.9 days. Approximately 10.2% of the shares of the company are sold short.

Institutional Investors Weigh In On scPharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. purchased a new stake in shares of scPharmaceuticals in the 1st quarter valued at about $33,000. Legato Capital Management LLC bought a new position in shares of scPharmaceuticals in the fourth quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. purchased a new stake in scPharmaceuticals in the fourth quarter valued at approximately $38,000. Virtu Financial LLC bought a new stake in scPharmaceuticals during the third quarter valued at approximately $46,000. Finally, ProShare Advisors LLC purchased a new position in scPharmaceuticals in the 4th quarter worth approximately $48,000. Institutional investors own 89.52% of the company's stock.

Wall Street Analyst Weigh In

SCPH has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Thursday, March 20th. Maxim Group cut their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 20th.

scPharmaceuticals Price Performance

Shares of scPharmaceuticals stock traded down $0.10 on Thursday, reaching $2.50. The stock had a trading volume of 229,903 shares, compared to its average volume of 356,145. The business's 50 day moving average is $2.86 and its two-hundred day moving average is $3.38. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals has a 1 year low of $1.94 and a 1 year high of $5.65. The company has a market cap of $125.71 million, a P/E ratio of -1.32 and a beta of 0.38.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. The business had revenue of $12.15 million for the quarter, compared to analysts' expectations of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. As a group, research analysts anticipate that scPharmaceuticals will post -1.53 EPS for the current year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.